Technical Analysis for DICE - DICE Therapeutics, Inc.

Grade Last Price % Change Price Change
C 26.05 -1.92% -0.51
DICE closed down 1.92 percent on Wednesday, March 22, 2023, on 1.27 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Earnings Movers Other -1.92%
Inside Day Range Contraction -1.92%
Earnings Movers Other -0.95%
Fell Below 20 DMA Bearish -9.61%
Inside Day Range Contraction -9.61%
Crossed Above 20 DMA Bullish -11.72%
Outside Day Range Expansion -11.72%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 10 hours ago
Up 3% about 10 hours ago
Possible NR7 about 11 hours ago
Up 2% about 11 hours ago
60 Minute Opening Range Breakout about 11 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


DICE Therapeutics, Inc. Description

DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It designs and develops therapies in immunology for patients with chronic diseases. The company's lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin and aVß1/aVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis. The company was founded in 2013 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Health Sciences Pharmacy Inflammation Inflammatory Bowel Disease Chronic Disease Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Interleukin 17

Is DICE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 45.99
52 Week Low 12.635
Average Volume 464,249
200-Day Moving Average 25.62
50-Day Moving Average 29.66
20-Day Moving Average 28.80
10-Day Moving Average 27.37
Average True Range 1.98
RSI 39.39
ADX 19.08
+DI 12.56
-DI 21.90
Chandelier Exit (Long, 3 ATRs) 27.12
Chandelier Exit (Short, 3 ATRs) 31.64
Upper Bollinger Bands 32.39
Lower Bollinger Band 25.20
Percent B (%b) 0.12
BandWidth 24.97
MACD Line -0.88
MACD Signal Line -0.65
MACD Histogram -0.2343
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.16
Resistance 3 (R3) 28.36 27.86 27.81
Resistance 2 (R2) 27.86 27.32 27.76 27.69
Resistance 1 (R1) 26.96 26.99 26.71 26.75 27.57
Pivot Point 26.46 26.46 26.33 26.35 26.46
Support 1 (S1) 25.55 25.92 25.30 25.35 24.53
Support 2 (S2) 25.05 25.59 24.95 24.41
Support 3 (S3) 24.15 25.05 24.29
Support 4 (S4) 23.94